GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shockwave Medical Inc (NAS:SWAV) » Definitions » Sloan Ratio %

Shockwave Medical (Shockwave Medical) Sloan Ratio % : 41.49% (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shockwave Medical Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Shockwave Medical's Sloan Ratio for the quarter that ended in Mar. 2024 was 41.49%.

Warning Sign:

When sloan ratio (36.83)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Mar. 2024, Shockwave Medical has a Sloan Ratio of 41.49%, indicating earnings are more likely to be made up of accruals.


Shockwave Medical Sloan Ratio % Historical Data

The historical data trend for Shockwave Medical's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shockwave Medical Sloan Ratio % Chart

Shockwave Medical Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial 24.38 41.52 -14.63 24.83 36.83

Shockwave Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.24 25.61 32.96 36.83 41.49

Competitive Comparison of Shockwave Medical's Sloan Ratio %

For the Medical Devices subindustry, Shockwave Medical's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shockwave Medical's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shockwave Medical's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Shockwave Medical's Sloan Ratio % falls into.



Shockwave Medical Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Shockwave Medical's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(147.278-196.053
--625.727)/1566.563
=36.83%

Shockwave Medical's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2024 )
=(163.499-197.931
--716.362)/1643.747
=41.49%

Shockwave Medical's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was 28.862 (Jun. 2023 ) + 34.986 (Sep. 2023 ) + 44.305 (Dec. 2023 ) + 55.346 (Mar. 2024 ) = $163.5 Mil.
Shockwave Medical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was 39.737 (Jun. 2023 ) + 50.651 (Sep. 2023 ) + 71.703 (Dec. 2023 ) + 35.84 (Mar. 2024 ) = $197.9 Mil.
Shockwave Medical's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -83.768 (Jun. 2023 ) + -305.879 (Sep. 2023 ) + -242.262 (Dec. 2023 ) + -84.453 (Mar. 2024 ) = $-716.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shockwave Medical  (NAS:SWAV) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, Shockwave Medical has a Sloan Ratio of 41.49%, indicating earnings are more likely to be made up of accruals.


Shockwave Medical Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Shockwave Medical's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Shockwave Medical (Shockwave Medical) Business Description

Traded in Other Exchanges
Address
5403 Betsy Ross Drive, Santa Clara, CA, USA, 95054
ShockWave Medical Inc is a medical device company focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Its intravascular lithotripsy technology is used in the treatment of calcified plaque. Geographically, the company generates its revenue from the United States, Europe and other countries.
Executives
Douglas Evan Godshall director, officer: President & CEO SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Frank T Watkins director 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Isaac Zacharias officer: Chief Commercial Officer 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Dan Puckett officer: CFO & Secretary 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Trinh Phung officer: VP, Finance C/O SHOCKWAVE MEDICAL, INC., 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Laura Francis director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Sara Toyloy director C/O SHOCKWAVE MEDICAL, INC., 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Kevin J. Ballinger director C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Antoine Papiernik director, 10 percent owner 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Sofinnova Capital Vii Fcpr 10 percent owner C/O SOFINNOVA PARTNERS, 18 RUE DU 4 SEPTEMBRE, 75002 PARIS I0 00000
Cahill Colin director 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Frederic H Moll director C/O INTUITIVE SURGICAL INC, 950 KIFER ROAD, SUNNYVALE CA 94086
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Larkin C Raymond Jr director C/O MALLINCKRODT INC, 7733 FORSYTH BLVD, ST LOUIS MO 63105